


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the above-referenced application.


Listing of Claims:

What is claimed is:

1. (Original) A c-Kit kinase inhibitor comprising as an active ingredient, a compound represented by the general formula (I), a salt thereof or a hydrate of the foregoing:



(wherein R^1 represents methyl, 2-methoxyethyl or a group represented by the formula (II):



(wherein R^{a3} represents methyl, cyclopropylmethyl or cyanomethyl; R^{a1} represents hydrogen, fluorine or hydroxyl; and R^{a2} represents 1-pyrrolydiny, 1-piperidiny, 4-morpholinyl, dimethylamino or diethylamino);

R^2 represents cyano or $-\text{CONHR}^{a4}$ (wherein R^{a4} represents hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy or C_{3-8} cycloalkoxy);

R^3 represents hydrogen, methyl, trifluoromethyl, chlorine or fluorine; and

R^4 represents hydrogen, methyl, ethyl, n-propyl, cyclopropyl, 2-thiazolyl or 4-fluorophenyl).

2. (Original) The c-Kit kinase inhibitor according to claim 1, wherein R¹ represents methyl.
3. (Original) The c-Kit kinase inhibitor according to claim 1, wherein R⁴ represents methyl, ethyl or cyclopropyl.
4. (Original) The c-Kit kinase inhibitor according to claim 1, wherein R³ represents hydrogen, chlorine or fluorine.
5. (Original) The c-Kit kinase inhibitor according to claim 1, wherein R² represents -CONHR^{a4} (wherein R^{a4} represents hydrogen or methoxy).
6. (Original) The c-Kit kinase inhibitor according to claim 1, wherein the compound represented by the general formula (I) is a compound selected from the group consisting of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide.
7. (Original) An anticancer agent for treating a cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase, comprising as an active ingredient, the c-Kit kinase inhibitor according to claim 1.
8. (Original) The anticancer agent according to claim 7, wherein the cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase is acute myelogenous leukemia, mast cell leukemia, a small cell lung cancer, GIST, a testicular cancer, an ovarian cancer, a breast cancer, a brain cancer, neuroblastoma or a colorectal cancer.
9. (Original) The anticancer agent according to claim 7, wherein the cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase is acute myelogenous leukemia, a small cell lung cancer or GIST.
10. (Original) The anticancer agent according to claim 7, which is applied to a patient for

which a cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase is identified.

11. (Original) A therapeutic agent for mastocytosis, allergy or asthma, comprising as an active ingredient, the c-Kit kinase inhibitor according to claim 1.

12. (Original) A therapeutic method for a cancer, comprising administering to a patient suffering from a cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase, a pharmacologically effective dose of the c-Kit kinase inhibitor according to claim 1.

13. (Original) The method according to claim 12, wherein the cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase is acute myelogenous leukemia, mast cell leukemia, a small cell lung cancer, GIST, a testicular cancer, an ovarian cancer, a breast cancer, a brain cancer, neuroblastoma or a colorectal cancer.

14. (Original) The method according to claim 12, wherein the cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase is acute myelogenous leukemia, a small cell lung cancer or GIST.

15. (Original) A therapeutic method for a cancer, comprising the steps of:

extracting cancer cells from a patient suffering from a cancer;

confirming that the cancer cells are expressing excessive c-Kit kinase or a mutant c-Kit kinase;
and

administering to the patient a pharmacologically effective dose of the c-Kit kinase inhibitor according to claim 1.

16. (Original) A therapeutic method for mastocytosis, allergy or asthma, comprising administering to a patient suffering from the disease, a pharmacologically effective dose of the c-Kit kinase inhibitor according to claim 1.

17. (Original) A method for inhibiting the c-Kit kinase activity, comprising applying to a cell expressing excessive c-Kit kinase or a mutant c-Kit kinase, a pharmacologically effective

dose of the c-Kit kinase inhibitor according to claim 1.

18. (New) The method according to claim 12, wherein the compound represented by the general formula (I) is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

19. (New) The method according to claim 15, wherein the compound represented by the general formula (I) is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

20. (New) The method according to claim 17, wherein the compound represented by the general formula (I) is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.